Zhuhai HOPEGENES pharmaceutical research institute co. LTD

ADD:Room 1791, no.6, baohua road,

           hengqin new district, zhuhai city

Tel :+86-756-888888

E-mail:hopegenes@163.com

Zhuhai HOPEGENES pharmaceutical research institute co. LTD

 吉ICP备12003232号    Powered by : www.300.cn

 

R&D SERUICES

Treatment

Page view:

Through the diagnosis of tumor primary site type, all kinds of immune cells (TCM, NK, CIK, CTL, DC, T, etc.) were treated individually with the primary site antigen. Clinical trials have shown a 95% negative conversion rate for early cancer.